Certificate pursuant to Regulation 74(5) of SEBI (D&P) Regulations, 2018, for the quarter ended on 31.12.2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jenburkt Pharmaceuticals has submitted a routine quarterly compliance certificate to BSE under SEBI's Depositories and Participants Regulations, 2018. The certificate was issued by the company's Registrar and Transfer Agent, Bigshare Services Pvt. Ltd. It confirms that all physical share certificates received for dematerialization during the quarter ending 31 December 2025 were processed and confirmed to the depositories within the required 15-day timeline. The certificates have been mutilated and cancelled, and the depository names have been substituted in the register of members as the registered owners. This is a standard procedural filing required every quarter from listed companies.
This is a routine regulatory compliance filing with no material impact on the company's financials, operations, or stock price. It simply confirms the smooth functioning of share dematerialization processes.